Prof. Segev Barak
email: barakseg@post.tau.ac.il

Segev Barak
Segev Barak
Segev Barak
Segev Barak

Publications

Click here for our page in Google Scholar

REPRINT AVAILABILITY IS FOR PERSONAL USE ONLY- ANYONE DOWNLOADING REPRINTS AGREES TO OBEY ALL COPYRIGHT LAWS PERTAINING TO THE ARTICLE 

    1. Maier, H.B., Neyazi, M., Neyazi, A., Hillemacher, T., Pathak, H., Rhein, M., Bleich, S., Goltseker, K., Sadot-Sogrin, Y., Even-Chen, O., Frieling, H., Barak S.  (2020). Alcohol consumption alters Gdnf promoter methylation and expression in rats. Journal of Psychiatric Research, 121: 1-9. PDF
    2. Even-Chen O., Barak S. (2019).Inhibition of FGF receptor-1 suppresses alcohol consumption: role of PI3 kinase signaling in dorsomedial striatum. The Journal Of Neuroscience  39 (40), 7947-7957. PDF
    3. Gera R., Barak S., Schonberg T. (2019). Counterconditioning following memory retrieval diminishes the reinstatement of appetitive memories in humans. Scientific Reports 9(1):9213. PDF
    4. Even-Chen O., Barak S. (2019). The role of fibroblast growth factor 2 in drug addiction. European Journal of Neuroscience,50:2552–2561. PDF
    5. Goltseker, K., Hopf, F. W., Barak, S. (2019). Advances in behavioral animal models of alcohol use disorder. Alcohol, 74:73-82. PDF
    6. Ziv Y., Rahamim N., Lezmy N., Even Chen O., Shaham, O. Malishkevich A., Giladi E.. Elkon R., Gozes I., Barak S. (2019). Activity-dependent neuroprotective protein is a novel negative regulator of alcohol consumption in female mice. Neuropsychopharmacology, 44(2):415-424. PDF
    7. Barak, S., Ahmadiantehrani, S., Logrip, M. L., Ron, D. (2019). GDNF and alcohol use disorder. Addiction Biology, 24(3):335-343. PDF
    8. Goltseker, K., Barak, S. (2018). Flood-conditioned place aversion as a novel non-pharmacological aversive learning procedure in mice. Scientific Reports, 8(1), 7280. PDF
    9. Burstein O., Gale E., Handelsman A., Barak S., Franko M., Motsan S., Shamir A., Toledano R., Simhon O., Hirshler Y., Doron R. (2017). Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS One 12(11): e0188043. PDF
    10. Even-Chen O., Sadot-Sogrin Y., Shaham O., Barak S. (2017). Fibroblast growth factor 2 in the dorsomedial striatum is a novel positive regulator of alcohol consumption. The Journal Of Neuroscience 37(36):8742-8754. PDF
    11. Zipori D., Sadot-Sogrin Y., Goltseker K., Even-Chen O., Rahamim N., Shaham O., Barak S. (2017). Re-exposure to nicotine-associated context from adolescence enhances alcohol intake in adulthood. Scientific Reports 7(1):2479. PDF
    12. Goltseker K., Bolotin L., Barak S. (2017). Counterconditioning during reconsolidation prevents relapse of cocaine memories. Neuropsychopharmacology 42(3):716-726 .
    13. Ron D., Barak S. (2016). Molecular mechanisms underlying alcohol-drinking behaviours. Nature Reviews Neuroscience, 17: 576-591.
    14. Logrip M.L., Barak S., Warnault V. Ron D. (2015). Corticostriatal BDNF and alcohol addiction. Brain Research, 1628:60-67
    15. Barak S., Wang J., Ahmadiantehrani S., Ben Hamida S, Kells A.P., Forsayeth J., Bankiewicz K.S., Ron D. (2015) GDNF is an endogenous protector in the mesolimbic system against excessive alcohol consumption and relapse. Addiction Biology, 20: 629-642 
    16. Weiner I., Barak S. (2015). Latent Inhibition. In I.P. Stolerman and L.H Price (Eds) Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg.
    17. Carnicella S., Ron D., Barak S. (2014). Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol 48(3):243-52 
    18. Neasta J., Barak S., Ben Hamida, S., Ron D. (2014) mTOR: A Key Player in Neuroadaptations Induced by Drugs of Abuse. Journal of Neurochemistry 130(2):172-84
    19. Barak S., Liu F., Ben Hamida, S., Yowell V.Q, Neasta J., Kharazia V., Janak P.H., Ron D. (2013). Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse. Nature Neuroscience, 16, 1111-1117
    20. Ahmadiantehrani S., Barak S., Ron, D (2014). GDNF is a novel alcohol-responsive gene in the VTA: Implications for the development and persistence of excessive drinking. Addiction Biology 19(4):623-33
    21. Warnault V., Darque E., Levine A., Barak S., Ron D. (2013). Chromatin remodeling – a novel strategy to control excessive alcohol drinking. Translational Psychiatry 3, e231
    22. Davies D.L., Finn D., Barak S., Ron D., Liang J., Olsen R.W. (2013). Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcoholism: Clinical and Experimental Research 37(1):8-15
    23. Pichat Ph., ; Guillot E., Pruniaux M.P., Beeské S., Lopez-Grancha M., Genet E., Terranova J.P., Castro A., Sanchez J.A., Black M.D., Varty G., Weiner I., Arad M., Barak S., De Levie, A., Griebel G. (2012) SAR110894, a potent histamine H3-receptor antagonist, displays procognitive and awakening effects in rodents. Pharmacology, Biochemistry and Behavior, 102(2):203-214.
    24. Barak S., Ben Hamida S. (2012). Memory erasure, enhanced extinction and disrupted reconsolidation. Journal of Neuroscience 32(7):2250 –2251
    25. Barak S., Ahmadiantehrani S., Kharazia V., Ron, D. (2011). Positive autoregulatory feedback loop of GDNF in the ventral tegmental area: implications for alcohol abuse disorders. Translational Psychiatry, 1 (e60): 1-9
    26. Barak S., Carnicella S., Yowell Q.V., Ron D. (2011). Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. Journal of Neuroscience, 31(27):9885-9894.
    27. Gibb S.L., Jeanblanc J., Barak S., Yowell Q.V., Yaka R. and Ron D. (2011). Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward. Journal of Neuroscience, 31(6):2180-2187
    28. Barak S., Weiner I. (2011) Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacology, Biochemistry and Behavior, 99(2): 164-189
    29. Dresner E., Barak S. (2011). Auditory and textual conversational multitasking. The Electronic Journal of Communication 21(3)
    30. Barak S., Weiner I (2011). The M1/M4 preferring antagonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: A selectively nonselective compound that can target multiple symptom domains of schizophrenia? International Journal of Neuropsychopharmacology 14(9): 1233-1246
    31. Black M.D., Stevens R.J., Rogacki N., Featherstone R.E., Senyah Y., Giardino O., Borowsky B., temmelin J., Cohen C., Pichat Ph., Arad M., Barak S., De Levie A. Weiner I., Griebel G., Varty G.B. (2011). AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology, 215(1):149-63
    32. Wang J., Carnicella S., Ahmadiantehrani S., He D-Y., Barak S., Kharazia V., Ben Hamida S., Zapata A., Shippenberg T.S., Ron, D. (2010). Nucleus accumbens-derived GDNF is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. Journal of Neuroscience, 30(43):14502-14512
    33. Barak S., Weiner I. (2010) Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology, 35: 1073-1082
    34. Barak S., Weiner I (2010). Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology 209(2): 175-184
    35. Barak S. (2009). Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behavioural Brain Research, 204(2):335-51
    36. Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. (2009). Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 34 (7): 1753-1763
    37. Barak S., Weiner I. (2009). Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. International Journal of Neuropsychopharmacology, 12(2): 227-241
    38. Black M., Varty GB., Arad M., Barak S., De Levie A., Boulay D., Pichat Ph., Griebel G., Weiner I. (2009). Procognitive and antipsychotic efficacy of Glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia. Latent inhibition studies in the rat. Psychopharmacology, 202(1-3): 385-396
    39. Dresner E., Barak S. (2009). Effects of visual spatial structure on textual conversational multitasking. Communication Quarterly 57(1): 104-115
    40. Barak S., Weiner I. (2007). Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 32(5): 989-999
    41. Dresner E., Barak S. (2006). Conversational multitasking in interactive written discourse as a communication competence. Communication Reports 19(1): 70-78
  1.